Views On Radius Health Inc. (RDUS) From A Technical Perspective

The stock of Radius Health Inc. (NASDAQ:RDUS) increased by increased by $0.7 on Friday to finish at $20.10, up 3.61 percent. The last five days have seen an average of 12,374,221 shares of common stock traded. 10 times new highs were reached in the current year, with a gain of $2.24. The average number of shares traded over the last 20 days was 3,477,205, while the average volume over the last 50 days totaled 1,591,872.

RDUS stock appreciated 58.89% since last month. On 10/01/21, the company’s shares reached a one-month low of $12.10. The stock touched a high of $26.16 on 03/23/21, after rallying from a low of $11.95 in 52 weeks. The price of RDUS stock has risen by 12.54% or $2.24 this year, reaching a new high 10 times. Still, the stock price is down -23.17% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 26 days since Radius Health Inc. (RDUS) last reported insider trading activity on Sep 29. On Sep 29, 10% Owner BIOTECH TARGET N V acquired 100,000 shares at $12.95 each. This transaction resulted in the insider spending $1,294,500. On Sep 22, BIOTECH TARGET N V added 150,000 shares at a price of US$12.28. After the transaction, the insider now owns 7,605,714 shares. Principal Finance Accounting Chopas James George had earlier sold 370 shares on Mar 05 for $20.88 a share. The transaction was completed for $7,726.

For the three months ended June 29, Radius Health Inc.’s quick ratio was 2.10, while its current ratio was 2.30, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 92.90% percent. Radius Health Inc.’s EBITDA margin for the year ended June 29 was -33.83%, whereas its operating margin stood at -14.80% for the same period. Based on annual data, it had gross profit of $221.44 million and revenue of $238.65 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RDUS’s return on assets (ROA) during the last 12 months has been -30.70%. There was a -71.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 35.70%.

Earnings Surprise

According to Radius Health Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $51.8 million, while revenues rose by 3.26% to $56.26 million. It was predicted that Radius Health Inc.’s quarterly earnings would be -$0.35, but it ended up being -$0.33, beating the consensus by -6.10%. EBITDA was -$11.23 million for the quarter. At the end of Radius Health Inc.’s most recent quarter ended June 29, its liabilities totaled 419.94 million, while its total debt was $339.3 million. Equity owned by shareholders amounts to $47.27 million.

Technical Picture

Here’s a quick look at Radius Health Inc.’s (RDUS) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 85.16%, suggesting the stock is Overbought, with a 84.00% historical volatility rate.

The stochastic %K and %D were 64.74% and 69.48% respectively, while the average true range (ATR) was 1.52. Based on the 14-day stochastic reading of 73.32%, the RSI (14) reading is 79.86%. On the 9-day MACD Oscillator, the stock is at 2.67, and the 14-day reading is at 3.83.

Analyst Ratings

Analysts have assigned Radius Health Inc. (RDUS) an Hold rating. RDUS is a stock that is recommended for selling by 0 brokerage firms, while 6 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.

What is RDUS’s price target for the next 12 months?

The current consensus forecast for the stock is between $18.00 and $33.00, with a median target price of $22.00. In analyzing these forecasts, the average price target given by analysts for Radius Health Inc. (RDUS) is $23.86.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam